LONDON (Alliance News) - e-Therapeutics PLC said Thursday that the first patient has been enrolled in its phase Ib programme for cancer drug ETS2101.
The programme is investigating the drug in a combination with the standard of care for patients with newly diagnosed pancreatic cancer, and as a monotherapy for patients with primary hepatocellular carcinoma, a common type of liver cancer, or pancreatic cancer who have relapsed or refractory disease.
"This marks an important milestone for ETS2101 as its development programme begins to explore aspects of this agent's activity in specific cancer indications, alongside further aspects of dosing and safety. This study is directed towards further clinical development of the compound and will inform our understanding of the drug in this therapeutic area," said Development Director Steve Self in a statement.
Shares in e-Therapeutics are trading up 5.9% at 39.70 pence Thursday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
